What is The ICPD?
The ICPD operates as a specialized entity at the intersection of pharmacology, statistical analysis, and clinical medicine. By focusing on the optimization of dosing regimens, intervals, and durations for antibacterials, antifungals, and biologics, the firm effectively reduces the inherent risks associated with antimicrobial development. Their multidisciplinary team, comprised of Pharm.D., Ph.D., and M.D. scientists, leverages advanced laboratory infrastructure to bridge the gap between bench-side research and patient-centric outcomes. As a trusted advisor to both government bodies and private pharmaceutical enterprises, the ICPD provides the empirical data necessary to navigate the regulatory and clinical hurdles of modern drug discovery.
How much funding has The ICPD raised?
The ICPD has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in The ICPD
PPP
Public-Private Partnership
What's next for The ICPD?
With this late-stage capital, the ICPD is well-positioned to scale its translational medicine capabilities and expand its influence on global drug development standards. The strategic allocation of these funds will likely prioritize the enhancement of their proprietary analytical models and the expansion of their laboratory facilities to accommodate a broader range of therapeutic modalities. As the global demand for robust antimicrobial stewardship grows, the ICPD is poised to leverage its advisory expertise to influence policy and clinical practice, further cementing its status as an essential partner in the pharmaceutical value chain. Future growth will likely center on deepening institutional partnerships and refining the integration of pharmacodynamics into early-phase clinical trials.
See full The ICPD company page
